Clinical Respiratory Journal最新文献

筛选
英文 中文
Correction to “Treatment Approaches for Pulmonary Hypertension in Colombia: A Call to Action” 更正“哥伦比亚肺动脉高压的治疗方法:行动呼吁”
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-06-12 DOI: 10.1111/crj.70095
{"title":"Correction to “Treatment Approaches for Pulmonary Hypertension in Colombia: A Call to Action”","authors":"","doi":"10.1111/crj.70095","DOIUrl":"https://doi.org/10.1111/crj.70095","url":null,"abstract":"<p>\u0000 <span>G. G. Pitsiou</span>, “ <span>Treatment Approaches for Pulmonary Hypertension in Colombia: A Call to Action</span>,” <i>Clinical Respiratory Journal</i> <span>19</span>, no. <span>2</span> (<span>2025</span>), https://doi.org/10.1111/crj.70062.\u0000 </p><p>In the References section, reference section 3 is outdated and should be updated to</p><p>3. Μ. Machado-Duque, Α. Gaviria-Mendoza, L. F. Valladales-Restrepo, et al., “Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia,” <i>Clinical Respiratory Journal</i> 19, no. 2 (2025), https://doi.org/10.1111/crj.70063.</p><p>We apologize for this error.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70095","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Assessment of Tuberculosis in Patients With Chronic Mental Illness and Related Factors: A Population-Based Cohort Study in Taiwan 台湾慢性精神疾病患者结核病风险评估及相关因素:一项以人群为基础的队列研究
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-06-09 DOI: 10.1111/crj.70088
Li-Chen Hung, Pei-Tseng Kung, Tung-Han Tsai, Wen-Chen Tsai, Kuang-Hua Huang
{"title":"Risk Assessment of Tuberculosis in Patients With Chronic Mental Illness and Related Factors: A Population-Based Cohort Study in Taiwan","authors":"Li-Chen Hung,&nbsp;Pei-Tseng Kung,&nbsp;Tung-Han Tsai,&nbsp;Wen-Chen Tsai,&nbsp;Kuang-Hua Huang","doi":"10.1111/crj.70088","DOIUrl":"https://doi.org/10.1111/crj.70088","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Tuberculosis (TB) is a globally prevalent chronic infectious disease. The World Health Organization estimates that mental illnesses will become the leading cause of global disease burden in 2030. The inability to detect and provide proper treatment for TB in mental illness patients is an epidemic prevention blind spot. The objective of this study was to retrospectively compare the incidence of TB between the general public and mental illness patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study used data across Taiwan from 2002 to 2013. The National Health Insurance Research Database, Registry for Catastrophic Illness Patients, Tuberculosis Database, and Household Registration Records of Taiwan were analyzed. Propensity score matching was used to reduce basic characteristic differences between mental illness patients and the general public. The conditional Cox proportional hazards model and cumulative risk curve were used to compare their risk of developing TB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>It was shown that TB incidence was 87 and 71 per 100 000 person-years in mental illness patients and the general public, respectively. The risk of developing TB in mental illness patients was 1.48 times (95% CI: 1.38–1.59) that of the general public.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Mental illness patients are a high-risk population for TB and should be listed as key subjects for TB prevention and control.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System 食品药品监督管理局不良事件报告系统中30种最常见的肺栓塞药物的探索性研究
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-06-05 DOI: 10.1111/crj.70054
Hang Chen, Yiming Shen, Yinyu Mu, Shuguang Xu, Shimo Shen, Weiyu Shen, Zeyang Hu, Hongxiang Li, Keyue Qiu, Jiaheng Zhang, Zhe Chen, Guodong Xu
{"title":"An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System","authors":"Hang Chen,&nbsp;Yiming Shen,&nbsp;Yinyu Mu,&nbsp;Shuguang Xu,&nbsp;Shimo Shen,&nbsp;Weiyu Shen,&nbsp;Zeyang Hu,&nbsp;Hongxiang Li,&nbsp;Keyue Qiu,&nbsp;Jiaheng Zhang,&nbsp;Zhe Chen,&nbsp;Guodong Xu","doi":"10.1111/crj.70054","DOIUrl":"https://doi.org/10.1111/crj.70054","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Backgrounds</h3>\u0000 \u0000 <p>Pulmonary embolism (PE) is a common disease and a common cause of death. However, it is currently unclear which clinically common drugs can lead to PE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We collected, organized, and analyzed reports from the first quarter of 2018 to the fourth quarter of 2022. We performed disproportionality analysis algorithms to calculate reporting odds ratio (ROR), which could quantify the signal values of different adverse events (AEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We have screened a total of 3091 drugs, with AE containing “PE” and calculated the ROR signal values of the top 30 drugs reported and ranked them. TESTIM (ROR = 32.03[28.77–35.66]), BARICITINIB (ROR = 23.48[20.55–26.83]), and NUVARIANG (ROR = 19.89[17.13–23.10]) are the drugs with the strongest correlation with PE. In addition, among the 30 drugs with the strongest correlation with PE, most of which are Biologics &amp; Immunomodulators. Therefore, when using these 30 drugs, it is necessary to be alert to the possible risk of PE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In our study, we filtered 30 common drugs that could cause PE through the FAERS public database, which provides theoretical support for drug selection in the treatment of malignant tumors and IMID.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Application of Artificial Intelligence-Assisted Analysis of Invasive Pulmonary Adenocarcinoma Less Than 6 mm in Size: A Case Report and Literature Review 人工智能辅助分析6mm以下浸润性肺腺癌的成功应用:1例报告及文献复习
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-28 DOI: 10.1111/crj.70073
Lu Zhang, Dawei Yang, Xianwei Ye, Chunxue Bai
{"title":"Successful Application of Artificial Intelligence-Assisted Analysis of Invasive Pulmonary Adenocarcinoma Less Than 6 mm in Size: A Case Report and Literature Review","authors":"Lu Zhang,&nbsp;Dawei Yang,&nbsp;Xianwei Ye,&nbsp;Chunxue Bai","doi":"10.1111/crj.70073","DOIUrl":"https://doi.org/10.1111/crj.70073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Screening of lung nodules helps on early diagnosis of lung cancer, especially invasive pulmonary adenocarcinoma. Artificial intelligence (AI) has been applied in diagnosis of cancers. We used the AI-assisted lung nodule diagnostic system in the screening of lung nodules and lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 66-year-old male complained of coughs and nodules in the right lung of 3-year duration. A ground-glass opacity was found in the right upper lung by routine computed tomography (CT). He had no family history of cancer, genetic diseases, or infectious diseases. AI-assisted analysis found four nodules, of which one was with the risk of malignancy of 88% (LungRads3), one was with the risk of malignancy of 15% (LungRads2), and the other two were smaller in size and considered benign. The patient underwent a thoracoscopic wedge resection of the right upper lung. The intraoperative frozen section pathology report confirmed invasive pulmonary adenocarcinoma, grade II, and primarily of alveolar and adherent types without metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In summary, AI-assisted lung nodule diagnostic system is effective in the screening of lung nodules and the differentiation between benign and malignant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Relationship Between Anthropometric Variables and Lung Function in a Severe Smoking Community Population With Ventilatory Dysfunction 重度吸烟伴呼吸功能障碍人群的人体测量变量与肺功能的关系
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-28 DOI: 10.1111/crj.70076
Tiantian Cen, Zekai Cen, Xuan Chen, Zaichun Deng, Yiming Yu, Shanshan Wang, Hongying Ma
{"title":"The Relationship Between Anthropometric Variables and Lung Function in a Severe Smoking Community Population With Ventilatory Dysfunction","authors":"Tiantian Cen,&nbsp;Zekai Cen,&nbsp;Xuan Chen,&nbsp;Zaichun Deng,&nbsp;Yiming Yu,&nbsp;Shanshan Wang,&nbsp;Hongying Ma","doi":"10.1111/crj.70076","DOIUrl":"https://doi.org/10.1111/crj.70076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The World Health Organization estimated that 65 million individuals have chronic obstructive pulmonary disease (COPD). However, large numbers remain undiagnosed. Anthropometric variables and lung function are closely related, such as body mass index (BMI), waist circumference (WC), and waist-to-height ratio (WHtR). Therefore, it is essential to explore the relationship between anthropometric variables and lung function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We recruited 7679 severe smokers. Severe smoking was defined as a smoking index ≥ 20 pack-years. Among these participants, there are 6214 severe smokers with mild, moderate, and moderately severe obstructive ventilation dysfunction and 1465 severe smokers with severe and very severe obstructive ventilation dysfunction. Otherwise, participants were divided into different groups according to questionnaires and sex.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Lung function in the severe smoking community population was associated with anthropometric variables. The study results showed that BMI was negatively associated with the risk of severe and very severe obstructive ventilation dysfunction in a severe smoking community population with ventilatory dysfunction (OR 0.791, 95% CI 0.691–0.907, <i>p</i> = 0.001), the COPD Population Screener (COPD-PS) scores ≥ 5 group (OR 0.787, 95% CI 0.688–0.902, <i>p</i> = 0.001), the COPD Screening Questionnaire (COPD-SQ) scores ≥ 16 group (OR 0.791, 95% CI 0.689–0.908, <i>p</i> = 0.001), the COPD-PS scores ≥ 5 and COPD-SQ scores ≥ 16 group (OR 0.730, 95% CI 0.603–0.884, <i>p</i> = 0.001) and the male group (OR 0.813, 95% CI 0.708–0.933, <i>p</i> = 0.003). The study showed that WC was also associated with obstructive ventilation dysfunction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Low BMI and WC were independent risk factors for severe and very severe obstructive ventilation dysfunction in the severe smoking community Chinese population with ventilatory dysfunction. Collecting COPD questionnaires may help manage lung function in the community population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages egfr突变的非小细胞肺癌脑转移患者的生存结局:Kaplan-Meier和Cox回归分析
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-27 DOI: 10.1111/crj.70085
Haoran Qi, Qiang Qiao, Xiaorong Sun, Ligang Xing
{"title":"Survival Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages","authors":"Haoran Qi,&nbsp;Qiang Qiao,&nbsp;Xiaorong Sun,&nbsp;Ligang Xing","doi":"10.1111/crj.70085","DOIUrl":"https://doi.org/10.1111/crj.70085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have shown significant efficacy in patients with brain metastases (BMs) from EGFR-mutated non-small cell lung cancer (NSCLC). However, acquired resistance is inevitable, and clinical data addressing key questions across treatment stages remain insufficient, limiting the formulation of precise treatment strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study analyzed 302 EGFR-mutant NSCLC patients with BMs treated at Shandong Cancer Hospital (2014–2022). Patients were divided into three cohorts: cohort A (first-/second-generation EGFR-TKIs without third-generation use), cohort B (first-/second-generation followed by third-generation EGFR-TKIs), and cohort C (first-line third-generation EGFR-TKIs). Survival outcomes were evaluated using Kaplan–Meier and Cox regression analyses across three treatment stages. Propensity score matching (PSM) adjusted for baseline imbalances.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Third-generation EGFR-TKIs demonstrated superior progression-free survival (PFS) in first-line therapy compared to earlier-generation agents (median PFS1: 14.2 vs. 11.2 months; <i>p</i> = 0.0021), particularly for intracranial control (median iPFS1: 18.0 vs. 12.2 months; <i>p</i> = 0.0058). Patients with uncommon EGFR mutations had significantly shorter PFS on third-generation EGFR-TKIs than those with common mutations (4.4 vs. 12.9 months; <i>p</i> = 0.012). After resistance, combination therapy with immune checkpoint inhibitors (ICIs), antiangiogenics, and chemotherapy extended overall survival (OS) versus non-ICI regimens (median OS2: 17.3 vs. 10.4 months; <i>p</i> = 0.004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Third-generation EGFR-TKIs are effective first-line options for BMs but show limited efficacy against uncommon mutations. Post-resistance regimens integrating ICIs, antiangiogenics, and chemotherapy may improve survival. Reassessment of genetic and PD-L1 status is critical for guiding sequential therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144140691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose of Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease and Risks of Osteoporosis or Fracture—A Systematic Review and Meta-Analysis 慢性阻塞性肺疾病患者吸入皮质类固醇剂量与骨质疏松或骨折风险:系统评价和荟萃分析
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-26 DOI: 10.1111/crj.70086
Wang Chun Kwok, Chung Ki Tsui, Sze Him Isaac Leung, Shuk Man Ngai, David Chi Leung Lam, Mary Sau Man Ip, James Chung Man Ho
{"title":"Dose of Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease and Risks of Osteoporosis or Fracture—A Systematic Review and Meta-Analysis","authors":"Wang Chun Kwok,&nbsp;Chung Ki Tsui,&nbsp;Sze Him Isaac Leung,&nbsp;Shuk Man Ngai,&nbsp;David Chi Leung Lam,&nbsp;Mary Sau Man Ip,&nbsp;James Chung Man Ho","doi":"10.1111/crj.70086","DOIUrl":"https://doi.org/10.1111/crj.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Inhaled corticosteroid (ICS) is a major pharmacotherapy for chronic obstructive pulmonary disease (COPD), which is associated with various adverse effects. Controversies exist in whether ICS use in COPD is associated with osteoporosis or fracture.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We performed a systematic review and meta-analysis to assess the risks of osteoporosis or fracture at different dosing levels of ICS. High-, medium- and low-dose ICS were defined according to the Global Initiative for Asthma (GINA) step definition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data sources</h3>\u0000 \u0000 <p>Cochrane, EMBASE, Ovid, PubMed and Web of Science were systematically searched until 8 December 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data extraction</h3>\u0000 \u0000 <p>Osteoporosis or fracture under ICS therapy was chosen as the primary efficacy outcome. Three reviewers were involved independently in the extraction process. The risk of bias of the included studies was evaluated by using different assessment tools.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-one RCTs and eight observational studies were included. High-dose ICS was associated with increased risks of osteoporosis or fracture in RCTs with RR of 1.14 (95% CI = 1.03–1.28), observational studies with healthy controls 1.14 (95% CI = 1.05–1.24) and observational studies without healthy controls 1.10 (95% CI = 1.01–1.21). High-dose ICS was associated with increased risks in fracture in RCTs with RR of 1.12 (95% CI = 1.03–1.23), observational studies with health controls 1.15 (95% CI = 1.05–1.25) and observational studies without healthy controls 1.13 (95% CI = 1.03–1.24). Medium- and low-dose ICS were not associated with osteoporosis or fracture.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>High-dose, but not medium- and low-dose, ICS use in COPD is associated with risks of osteoporosis or fractures.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144140341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA HOXA-AS2 Can Predict the Risk of Acute Respiratory Distress Syndrome and 28-Day Mortality in Patients With Sepsis LncRNA HOXA-AS2可以预测脓毒症患者急性呼吸窘迫综合征的风险和28天死亡率
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-21 DOI: 10.1111/crj.70082
Youhong Quan, Song Gao
{"title":"LncRNA HOXA-AS2 Can Predict the Risk of Acute Respiratory Distress Syndrome and 28-Day Mortality in Patients With Sepsis","authors":"Youhong Quan,&nbsp;Song Gao","doi":"10.1111/crj.70082","DOIUrl":"https://doi.org/10.1111/crj.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore the diagnostic and predictive value of lncRNA HOXA-AS2 for acute respiratory distress syndrome (ARDS) and 28-day mortality in sepsis patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The levels of HOXA-AS2 in sepsis and ARDS patients were detected by real-time quantitative reverse transcription PCR (RT-qPCR). The receiver operating curve (ROC) curve was used to evaluate the diagnostic value of HOXA-AS2 for sepsis and ARDS. The K-M curve was used to evaluate the effect of HOXA-AS2 on the prognosis. Logistic regression analysis and COX regression analysis were used to explore the risk factors influencing ARDS and death. Additionally, an ARDS cell model was constructed to explore the effects of HOXA-AS2 on cell viability, inflammation, and endothelial glycocalyx.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>HOXA-AS2 decreased in sepsis patients who developed ARDS and died. This molecule can not only serve as a diagnostic marker for sepsis but also act as a risk factor to predict the risk of ARDS and death within 28 days in patients with sepsis. Sepsis patients with low levels of HOXA-AS2 are more prone to ARDS and death. In cells attacked by lipopolysaccharide (LPS), overexpression of HOXA-AS2 inhibited apoptosis, inflammation, and the degradation of endothelial glycocalyx.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In sepsis patients, HOXA-AS2 has the potential to serve as a predictive marker for ARDS and 28-day mortality. This molecule may delay the progression of ARDS by inhibiting inflammation and the degradation of the endothelial glycocalyx.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic and Prognostic Potential of G Protein-Coupled Receptors in Lung Adenocarcinoma: Evidence From Transcriptome Data and In Vitro Experiments
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-13 DOI: 10.1111/crj.70080
Feiyan Yang, Jianye Yang, Guobiao Yang, Ya Zhang
{"title":"Therapeutic and Prognostic Potential of G Protein-Coupled Receptors in Lung Adenocarcinoma: Evidence From Transcriptome Data and In Vitro Experiments","authors":"Feiyan Yang,&nbsp;Jianye Yang,&nbsp;Guobiao Yang,&nbsp;Ya Zhang","doi":"10.1111/crj.70080","DOIUrl":"https://doi.org/10.1111/crj.70080","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>G protein-coupled receptors (GPCRs), the largest family of cell-surface molecules involve in various signal transduction, have recently been recognized as important drivers of cancer. However, few studies have reported on the potential of GPCRs as therapeutic targets or biomarkers in lung adenocarcinoma (LUAD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The expression profiles and clinical data of LUAD in the GSE30219 and GSE18842 datasets of the Cancer Genome Atlas were analyzed. LUAD-associated module genes were screened utilizing weighted gene co-expression network analysis (WGCNA). Prognostic signature genes were identified by univariate Cox survival analysis, LASSO regression, and multivariate Cox regression analyses. The immune status was evaluated and drug sensitivity was determined, conducting in vitro experiments for validation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with LUAD exhibited lower GPCR score than the controls, and 38 dysregulated GPCRs were identified by screening with differential analysis and WGCNA module genes. An optimal prognostic signature was identified, including OR51E1, LGR4, ADRB1, ADGRD1, and ADGRE3. The model established based on these five genes harbored moderate predictive performance for the survival of patients with LUAD. The risk score was negatively correlated with the infiltrating levels of multiple immune cells, including M2 macrophages, myeloid dendritic cells, and neutrophils, but positively correlated with fewer immune cells, such as Th1/Th2 CD4 + T cell. ADGRE3 and OR51E1 expression was positively correlated with drug sensitivity, including to cisplatin, ribociclib, and pevonedistat. Silencing OR51E1 inhibited the malignant cytological behaviors of LUAD cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GPCRs demonstrated prognostic potential in LUAD, with five genes identified as potential therapeutic targets and prognostic biomarkers for LUAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pressure Properties of a New Positive Expiratory Pressure Device—OpenUp Flow a Three-in-One Solution 一种新型呼气正压装置的压力特性-开启流三合一解决方案
IF 1.9 4区 医学
Clinical Respiratory Journal Pub Date : 2025-05-13 DOI: 10.1111/crj.70084
Pär Wennberg, Bengt Sundberg, Elisabeth Westerdahl
{"title":"Pressure Properties of a New Positive Expiratory Pressure Device—OpenUp Flow a Three-in-One Solution","authors":"Pär Wennberg,&nbsp;Bengt Sundberg,&nbsp;Elisabeth Westerdahl","doi":"10.1111/crj.70084","DOIUrl":"https://doi.org/10.1111/crj.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A new flow-regulated PEP device has been evaluated regarding functionality and pressure properties.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The three different resistance levels were assessed and evaluated at standardized flow rates of 10 and 18 L/min; Kruskal–Wallis test was used to analyse the differences in generated pressure between the different resistance levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A range of 3–31 cmH<sub>2</sub>O was generated with airflows of 10 and 18 L/min. There was a significant difference in pressure among different resistance levels at both flow rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, there was a significant difference in pressure among different resistance levels at both flow rates, showing that the high resistance significantly increased pressure compared with low resistance. This new device is performing comparable with other resistors available in the market.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 5","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信